Browse by Research Team

Article

Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
Tölle, M., Gökbuget, N., Habringer, S., Keller, U. and Schwartz, S.
Annals of Hematology 11 May 2024 (In Press)

Association of an impaired GH‑IGF‑I axis with cardiac wasting in patients with advanced cancer.
Fröhlich, A.K., Porthun, J., Talha, K.M., Lena, A., Hadzibegovic, S., Wilkenshoff, U., Sonntag, F., Nikolski, A., Ramer, L.V., Zeller, T., Keller, U., Bullinger, L., Anker, S.D., Haverkamp, W., von Haehling, S., Doehner, W., Rauch, U., Skurk, C., Cleland, J.G.F., Butler, J., Coats, A.J.S., Landmesser, U., Karakas, M. and Anker, M.S.
Clinical Research in Cardiology 8 April 2024 (In Press)

CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen [CXCR4-targeted theranostics in hematooncology: opportunities and challenges].
Werner, R., Haug, A., Buske, C., Heidegger, S., Illert, A.L., Bassermann, F., Herhaus, P., Buck, A., Duell, J., Topp, M.S., Kraus, S., Einsele, H., Lapa, C., Raderer, M., Lenz, G., Habringer, S., von Tresckow, B. and Keller, U.
Nuklearmedizin 63 (2): 57-61. April 2024

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Baumgartner, F., Baer, C., Bamopoulos, S.A., Ayoub, E., Truger, M., Meggendorfer, M., Lenk, M., Hoermann, G., Hutter, S., Müller, H., Walter, W., Mueller, M.L., Nadarajah, Ni., Blombery, P., Keller, U., Kern, W., Haferlach, C. and Haferlach, T.
Blood 143 (12): 1139-1156. 21 March 2024

Activation of gp130 signaling in T cells drives T(H)17-mediated multi-organ autoimmunity.
Baumgartner, F., Bamopoulos, S.A., Faletti, L., Hsiao, H.J., Holz, M., Gonzalez-Menendez, I., Solé-Boldo, L., Horne, A., Gosavi, S., Özerdem, C., Singh, N., Liebig, S., Ramamoorthy, S., Lehmann, M., Demel, U., Kühl, A.A., Wartewig, T., Ruland, J., Wunderlich, F.T., Schick, M., Walther, W., Rose-John, S., Haas, S., Quintanilla-Martinez, L., Feske, S., Ehl, S., Glauben, R. and Keller, U.
Science Signaling 17 (824): eadc9662. 20 February 2024

Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.
Stögbauer, F., Otto, R., Jöhrens, K., Tinhofer, I., Keilholz, U., Poremba, C., Keller, U., Leser, U., Weichert, W., Boxberg, M. and Klinghammer, K.
Oral Oncology 149 : 106678. February 2024

Renal extramedullary hematopoiesis in mast cell leukemia with bone marrow fibrosis.
Rieke, D.T., Schmalbrock, L.K., Ihlow, J., Kleo, K., von Brünneck, A.C., Nolte, F., Keller, U. and Ochsenreither, S.
Case Reports in Hematology 2024 : 1-6. 3 January 2024

A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
Habringer, S., Demel, U.M., Fietz, A.K., Lammer, F., Schroers, R., Hofer, S., Bairey, O., Braess, J., Meier-Stiegen, A.S., Stuhlmann, R., Schmidt-Hieber, M., Hoffmann, J., Zinngrebe, B., Kaiser, U., Reimer, P., Möhle, R., Fix, P., Höffkes, H.G., Langenkamp, U., Büschenfelde, C.M.Z., Hopfer, O., Stoltefuß, A., La Rosée, P., Blasberg, H., Jordan, K., Kaun, S., Meurer, A., Unteroberdörster, M., von Brünneck, A.C., Capper, D., Heppner, F.L., Chapuy, B., Janz, M., Schwartz, S., Konietschke, F., Vajkoczy, P., Korfel, A. and Keller, U.
European Journal of Cancer 196 : 113436. January 2024

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
Fuchs, M., Jacob, A.S., Kaul, H., Kobe, C., Kuhnert, G., Pabst, T., Greil, R., Bröckelmann, P.J., Topp, M.S., Just, M., Hertenstein, B., Soekler, M., Vogelhuber, M., Zijlstra, J.M., Keller, U.B., Krause, S.W., Dührsen, U., Meissner, J., Viardot, A., Eich, H.T., Baues, C., Diehl, V., Rosenwald, A., Buehnen, I., von Tresckow, B., Dietlein, M., Borchmann, P., Engert, A. and Eichenauer, D.A.
Leukemia 38 (1): 160-167. January 2024

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass.
Habringer, S., Ihlow, J., Kleo, K., Klostermann, A., Schmidt, M., Chai, L., Knödler, M., Leyvraz, S., Sigler, C., Sinn, B., Maschmeyer, G., Jegodka, Y., Benary, M., Ott, C.E., Tinhofer, I., Schäfer, R., Möbs, M., Keller, U., Keilholz, U. and Rieke, D.T.
Oncologist : oyae137. 2024 (In Press)

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities.
Ramberger, E., Sapozhnikova, V., Ng, Y.L.D., Dolnik, A., Ziehm, M., Popp, O., Sträng, E., Kull, M., Grünschläger, F., Krüger, J., Benary, M., Müller, S., Gao, X., Murgai, A., Haji, M., Schmidt, A., Lutz, R., Nogai, A., Braune, J., Laue, D., Langer, C., Khandanpour, C., Bassermann, F., Döhner, H., Engelhardt, M., Straka, C., Hundemer, M., Beule, D., Haas, S., Keller, U., Einsele, H., Bullinger, L., Knop, S., Mertins, P. and Krönke, J.
Nature Cancer 2024 (In Press)

Characterization of nucleolar SUMO isopeptidases unveils a general p53-independent checkpoint of impaired ribosome biogenesis.
Dönig, J., Mende, H., Davila Gallesio, J., Wagner, K., Hotz, P., Schunck, K., Piller, T., Hölper, S., Uhan, S., Kaulich, M., Wirth, M., Keller, U., Tascher, G., Bohnsack, K.E. and Müller, S.
Nature Communications 14 (1): 8121. 8 December 2023

Leveraging large language models for decision support in personalized oncology.
Benary, M., Wang, X.D., Schmidt, M., Soll, D., Hilfenhaus, G., Nassir, M., Sigler, C., Knödler, M., Keller, U., Beule, D., Keilholz, U., Leser, U. and Rieke, D.T.
JAMA Network Open 6 (11): e2343689. November 2023

Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients.
Panagiota, V., Kerschbaum, J.F., Penack, O., Stein, C.M., Arends, C.M., Koenecke, C., Strzelecka, P.M., Kloos, A., Wiegand, L., Lasch, A., Altwasser, R., Halik, A., Gabdoulline, R., Thomson, J., Weibl, K., Franke, G.N., Berger, C., Hasenkamp, J., Ayuk, F., Na, I.K., Beutel, G., Keller, U., Bullinger, L., Wulf, G.G., Kröger, N., Vucinic, V., Heuser, M. and Damm, F.
HemaSphere 7 (10): e957. October 2023

Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment.
Burmeister, T., Gröger, D., Gökbuget, N., Spriewald, B., Starck, M., Elmaagacli, A., Hoelzer, D., Keller, U. and Schwartz, S.
Scientific Reports 13 (1): 15167. 13 September 2023

Predictors of lower exercise capacity in patients with cancer.
Evertz, R., Diehl, C., Gödde, K., Valentova, M., Garfias-Veitl, T., Overbeck, T.R., Braulke, F., Lena, A., Hadzibegovic, S., Bleckmann, A., Keller, U., Landmesser, U., König, A.O., Hasenfuss, G., Schuster, A., Anker, M.S. and von Haehling, S.
Scientific Reports 13 (1): 14861. 8 September 2023

Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
Zhang, L., Wirth, M., Patra, U., Stroh, J., Isaakidis, K., Rieger, L., Kossatz, S., Milanovic, M., Zang, C., Demel, U., Keiten-Schmitz, J., Wagner, K., Steiger, K., Rad, R., Bassermann, F., Müller, S., Keller, U. and Schick, M.
EMBO Molecular Medicine 15 (9): e16431. September 2023

Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire.
Anker, M.S., Potthoff, S.K., Lena, A., Porthun, J., Hadzibegovic, S., Evertz, R., Denecke, C., Fröhlich, A.K., Sonntag, F., Regitz-Zagrosek, V., Rosen, S.D., Lyon, A.R., Lüscher, T.F., Spertus, J.A., Anker, S.D., Karakas, M., Bullinger, L., Keller, U., Landmesser, U., Butler, J. and von Haehling, S.
European Journal of Heart Failure 25 (9): 1635-1647. September 2023

Tumour mutational burden and survival with molecularly matched therapy.
de Bortoli, T., Benary, M., Horak, P., Lamping, M., Stintzing, S., Tinhofer, I., Leyvraz, S., Schäfer, R., Klauschen, F., Keller, U., Stenzinger, A., Fröhling, S., Kurzrock, R., Keilholz, U., Rieke, D.T. and Jelas, I.
European Journal of Cancer 190 : 112925. September 2023

Hand grip strength in patients with advanced cancer: a prospective study.
Hadzibegovic, S., Porthun, J., Lena, A., Weinlaänder, P., Lück, L.C., Potthoff, S.K., Rösnick, L., Fröhlich, A.K., Ramer, L.V., Sonntag, F., Wilkenshoff, U., Ahn, J., Keller, U., Bullinger, L., Mahabadi, A.A., Totzeck, M., Rassaf, T., von Haehling, S., Coats, A.J.S., Anker, S.D., Roeland, E.J., Landmesser, U. and Anker, M.S.
Journal of Cachexia Sarcopenia and Muscle 14 (4): 1682-1694. August 2023

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
Kayser, S., Martínez-Cuadrón, D., Rodriguez-Veiga, R., Hänel, M., Tormo, M., Schäfer-Eckart, K., Botella, C., Stölzel, F., Del Castillo, T.B., Keller, U., Rodriguez-Medina, C., Held, G., Amigo, M.L., Schliemann, C., Colorado, M., Kaufmann, M., Garcia, M.B., Krause, S.W., Görner, M., Jost, E., Steffen, B., Zukunft, S., Platzbecker, U., Ho, A.D., Baldus, C.D., Serve, H., Müller-Tidow, C., Thiede, C., Bornhäuser, M., Montesinos, P., Röllig, C. and Schlenk, R.F.
Haematologica 108 (8): 2059-2066. August 2023

Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer.
Anker, M.S., Lena, A., Roeland, E.J., Porthun, J., Schmitz, S., Hadzibegovic, S., Sikorski, P., Wilkenshoff, U., Fröhlich, A.K., Ramer, L.V., Rose, M., Eucker, J., Rassaf, T., Totzeck, M., Lehmann, L.H., von Haehling, S., Coats, A.J.S., Friede, T., Butler, J., Anker, S.D., Riess, H., Landmesser, U., Bullinger, L., Keller, U. and Ahn, J.
Journal of Cachexia Sarcopenia and Muscle 14 (4): 1670-1681. August 2023

Variable outcomes of hepatitis E infections in patients with hemato-oncologic diseases.
Ingwersen, V., Hofmann, J., Muche, M., Le Coutre, P., Schneider, T., Leng, C., Burmeister, T., Maschmeyer, G., Keller, U. and Schwartz, S.
Oncology Research and Treatment 46 (7-8): 296-302. August 2023

Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
Martin, S., Viertl, D., Janz, A., Habringer, S., Keller, U. and Schottelius, M.
EJNMMI Research 13 (1): 40. 10 May 2023

Clinical and prognostic relevance of cardiac wasting in patients with advanced cancer.
Lena, A., Wilkenshoff, U., Hadzibegovic, S., Porthun, J., Rösnick, L., Fröhlich, A.K., Zeller, T., Karakas, M., Keller, U., Ahn, J., Bullinger, L., Riess, H., Rosen, S.D., Lyon, A.R., Lüscher, T.F., Totzeck, M., Rassaf, T., Burkhoff, D., Mehra, M.R., Bax, J.J., Butler, J., Edelmann, F., Haverkamp, W., Anker, S.D., Packer, M., Coats, A.J.S., von Haehling, S., Landmesser, U. and Anker, M.S.
Journal of the American College of Cardiology 81 (16): 1569-1586. 25 April 2023

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen, G.J.J.E., Baumgartner, F., Heider, M., Patra, U., Holz, M., Braune, J., Kaiser, M., Schäffer, I., Bamopoulos, S.A., Ramberger, E., Murgai, A., Ng, Y.L.D., Demel, U.M., Laue, D., Liebig, S., Krüger, J., Janz, M., Nogai, A., Schick, M., Mertins, P., Müller, S., Bassermann, F., Krönke, J., Keller, U. and Wirth, M.
Blood Advances 7 (4): 469-481. 28 February 2023

Cardiovascular and metabolic determinants of quality of life in patients with cancer.
Evertz, R., Gödde, K., Diehl, C., Valentova, M., Garfias-Veitl, T., Braulke, F., Wulf, G.G., Overbeck, T.R., Bleckmann, A., König, A.O., Weinländer, P., Potthoff, S., Hadzibegovic, S., Lena, A., Keller, U., Landmesser, U., Schuster, A., Anker, M.S., Hasenfuß, G. and von Haehling, S.
ESC Heart Failure 10 (1): 167-176. February 2023

Small molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.
Demel, U.M., Wirth, M., Yousefian, S., Zhang, L., Isaakidis, K., Dönig, J., Böger, M., Singh, N., Köse, H., Haas, S., Müller, S., Schick, M. and Keller, U.
Haematologica 108 (2): 555-567. February 2023

Target selection for T-cell therapy in epithelial ovarian cancer: systematic prioritization of self-antigens.
Schossig, P., Coskun, E., Arsenic, R., Horst, D., Sehouli, J., Bergmann, E., Andresen, N., Sigler, C., Busse, A., Keller, U. and Ochsenreither, S.
International Journal of Molecular Sciences 24 (3): 2292. 24 January 2023

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Rieke, D.T., Schröder, S., Schafhausen, P., Blanc, E., Zuljan, E., von der Emde, B., Beule, D., Keller, U., Keilholz, U. and Klinghammer, K.
Frontiers in Oncology 13 : 1107134. 2023

Relapse of NPM1-mutated AML with extramedullary manifestation 17 years after allogeneic hematopoietic stem cell transplantation.
Braune, J., Rieger, K., Blau, O., Keller, U., Bullinger, L. and Krönke, J.
Case Reports in Hematology 2022 : 3317936. 28 December 2022

The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma.
Paulmann, C., Spallek, R., Karpiuk, O., Heider, M., Schäffer, I., Zecha, J., Klaeger, S., Walzik, M., Öllinger, R., Engleitner, T., Wirth, M., Keller, U., Krönke, J., Rudelius, M., Kossatz, S., Rad, R., Kuster, B. and Bassermann, F.
EMBO Journal 41 (20): e110871. 17 October 2022

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis.
Kraus, S., Klassen, P., Kircher, M., Dierks, A., Habringer, S., Gäble, A., Kortüm, K.M., Weinhold, N., Ademaj-Kospiri, V., Werner, R.A., Schirbel, A., Buck, A.K., Herhaus, P., Wester, H.J., Rosenwald, A., Weber, W.A., Einsele, H., Keller, U., Rasche, L. and Lapa, C.
Theranostics 12 (13): 5986-5994. 8 August 2022

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri, A.J.M., Cwynarski, K., Pulczynski, E., Fox, C.P., Schorb, E., Celico, C., Falautano, M., Nonis, A., La Rosée, P., Binder, M., Fabbri, A., Ilariucci, F., Krampera, M., Roth, Al., Hemmaway, C., Johnson, P.W., Linton, K.M., Pukrop, T., Gørløv, J.S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Zanni, M., Krause, S.W., Schmoll, H.J., Hertenstein, B., Rummel, M., Smith, J., Thurner, L., Cabras, G., Pennese, E., Ponzoni, M., Deckert, M., Politi, L.S., Finke, J., Ferranti, A., Cozens, K., Burger, E., Ielmini, N., Cavalli, F., Zucca, E. and Illerhaus, G.
Leukemia 36 (7): 1870-1878. July 2022

Gene gun Her2/neu DNA vaccination: evaluation of vaccine efficacy in a syngeneic Her2/neu mouse tumor model.
Nguyen-Hoai, T., Hohn, O., Pezzutto, A. and Westermann, J.
Methods in Molecular Biology 2521 (3): 129-154. 23 June 2022

TCR gene therapy for cancer.
Rhein, S. and Çakmak-Görür, N.
Methods in Molecular Biology 2521 (3): 95-128. 23 June 2022

Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia.
Hegazy, A.N., Krönke, J., Angermair, S., Schwartz, S., Weidinger, C., Keller, U., Treskatsch, S., Siegmund, B. and Schneider, T.
BMC Infectious Diseases 22 (1): 537. 13 June 2022

Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Braitsch, K., Schwarz, A., Koch, K., Hubbuch, M., Menzel, H., Keller, U., Götze, K.S., Bassermann, F., Herhaus, P. and Verbeek, M.
Annals of Hematology 101 (6): 1311-1319. June 2022

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
Demel, U.M., Böger, M., Yousefian, S., Grunert, C., Zhang, L., Hotz, P.W., Gottschlich, A., Köse, H., Isaakidis, K., Vonficht, D., Grünschläger, F., Rohleder, E., Wagner, K., Dönig, J., Igl, V., Brzezicha, B., Baumgartner, F., Habringer, S., Löber, J., Chapuy, B., Weidinger, C., Kobold, S., Haas, S., Busse, A.B., Müller, S., Wirth, M., Schick, M. and Keller, U.
Journal of Clinical Investigation 132 (9): e152383. 2 May 2022

Isolation of neoantigen-specific human T cell receptors from different human and murine repertoires.
Grunert, C., Willimsky, G., Peuker, C.A., Rhein, S., Hansmann, L., Blankenstein, T., Blanc, E., Beule, D., Keller, U., Pezzutto, A. and Busse, A.
Cancers 14 (7): 1842. 6 April 2022

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess, G., Hüttmann, A., Witzens-Harig, M., Dreyling, M.H., Keller, U., Marks, R., Ernst, T., Pott, C., Viardot, A., Frontzek, F., Trautmann, M., Ruckes, C., Deuster, O., Rosenwald, A., Theobald, M. and Lenz, G.
British Journal of Haematology 198 (3): 482-491. 1 April 2022

90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger, K., De Filippi, R., Lindén, O., Viardot, A., Hess, G., Lerch, K., Neumeister, P., Stroux, A., Peuker, C.A., Pezzutto, A., Pinto, A., Keller, U. and Scholz, C.W.
Annals of Hematology 101 (4): 781-788. April 2022

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.
Doffo, J., Bamopoulos, S.A., Köse, H., Orben, F., Zang, C., Pons, M., den Dekker, A.T., Brouwer, R.W.W., Baluapuri, A., Habringer, S., Reichert, M., Illendula, A., Krämer, O.H., Schick, M., Wolf, E., van IJcken, W.F.J., Esposito, I., Keller, U., Schneider, G. and Wirth, M.
Proceedings of the National Academy of Sciences of the United States of America 119 (9): e2105691119. 1 March 2022

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Ng, Y.L.D., Ramberger, E., Bohl, S.R., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., Gütschow, M., Döhner, H., Walther, W., Keller, U., Bullinger, L., Mertins, P. and Krönke, J.
Nature Communications 13 (1): 1009. 23 February 2022

Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial.
Kaddu-Mulindwa, D., Lesan, V., Berdel, C., Stilgenbauer, S., Bewarder, M., Thurner, L., Witzens-Harig, M., Viardot, A., Soekler, M., Keller, U., Truemper, L., Christofyllakis, K., Fleser, O., Bittenbring, J.T., Poeschel, V., Held, G. and Jagoda, P.
Leukemia & Lymphoma 63 (2): 326-334. February 2022

Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
Peuker, C.A., Yaghobramzi, S., Grunert, C., Keilholz, L, Gjerga, E., Hennig, S., Schaper, S., Na, I.K., Keller, U., Brucker, S., Decker, T., Fasching, P., Fehm, T., Janni, W., Kümmel, S., Schneeweiss, A., Schuler, M., Lüftner, D. and Busse, A.
European Journal of Cancer 162 : 45-55. February 2022

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Stroh, J., Seckinger, A., Heider, M., Rudelius, M., Eichner, R., Schick, M., Slawska, J., Emde, M., Salwender, H., Bertsch, U., Goldschmidt, H., Weisel, K.C., Scheid, C., Keller, U., Hose, D. and Bassermann, F.
Blood Advances 6 (2): 515-520. 25 January 2022

Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.
Schick, M., Zhang, L., Maurer, S., Maurer, H.C., Isaakaidis, K., Schneider, L., Patra, U., Schunck, K., Rohleder, E., Hofstetter, J., Baluapuri, A., Scherger, A.K., Slotta-Huspenina, J., Hettler, F., Weber, J., Engleitner, T., Maresch, R., Slawska, J., Lewis, R., Istvanffy, R., Habringer, S., Steiger, K., Baiker, A., Oostendorp, R.A.J., Miething, C., Lenhof, H.P., Bassermann, F., Chapuy, B., Wirth, M., Wolf, E., Rad, R., Müller, S. and Keller, U.
Nature Communications 13 (1): 281. 12 January 2022

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals.
Denker, S., Bittner, A., Frick, M., Kase, J., Hoffmann, J., Trenker, C., Keller, U., Bogner, C., Hüttmann, A., Dürig, J., Janz, M., Mathas, S., Marks, R., Krohn, U., Na, I.K., Bullinger, L. and Schmitt, C.A.
Leukemia & Lymphoma 63 (1): 84-92. January 2022

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study.
Kayser, S., Schlenk, R.F., Lebon, D., Carre, M., Götze, K.S., Stölzel, F., Berceanu, A., Schäfer-Eckart, K., Peterlin, P., Hicheri, Y., Rahme, R., Raffoux, E., Chermat, F., Krause, S.W., Aulitzky, W.E., Rigaudeau, S., Noppeney, R., Berthon, C., Görner, M., Jost, E., Carassou, P., Keller, U., Orvain, C., Braun, T., Saillard, C., Arar, A., Kunzmann, V., Wemeau, M., De Wit, M., Niemann, D., Bonmati, C., Schwänen, C., Abraham, J., Aljijakli, A., Haiat, S., Krämer, A., Reichle, A., Gnadler, M., Willekens, C., Spiekermann, K., Hiddemann, W., Müller-Tidow, C., Thiede, C., Röllig, C., Serve, H., Bornhäuser, M., Baldus, C.D., Lengfelder, E., Fenaux, P., Platzbecker, U. and Adès, L.
Haematologica 106 (12): 3100-3106. December 2021

Survey of long-term experiences of sperm cryopreservation in oncological and non-oncological patients: usage and reproductive outcomes of a large monocentric cohort.
Lackamp, N., Wilkemeyer, I., Jelas, I., Keller, U., Bullinger, L., Stintzing, S. and le Coutre, P.
Frontiers in Oncology 11 : 772809. 5 November 2021

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
Lewis, R., Maurer, H.C., Singh, N., Gonzalez-Menendez, I., Wirth, M., Schick, M., Zhang, L., Isaakidis, K., Scherger, A.K., Schulze, V., Lu, J., Zenz, T., Steiger, K., Rad, R., Quintanilla-Martinez, L., Espeli, M., Balabanian, K., Keller, U. and Habringer, S.
Leukemia 35 : 2895-2905. October 2021

The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL - results from the phase-II STORM trial.
Witzens-Harig, M., Viardot, A., Keller, U., Wosniok, J., Deuster, O., Klemmer, J., Geueke, A.M., Meißner, J., Ho, A.D., Atta, J., Marks, R., La Rosée, P., Buske, C., Dreyling, M.H. and Hess, G.
HemaSphere 5 (10): e636. October 2021

Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients.
Lewis, R., Habringer, S., Kircher, M., Hefter, M., Peuker, C.A., Werner, R., Ademaj-Kospiri, V., Gäble, A., Weber, W., Wester, H.J., Buck, A., Herhaus, P., Lapa, C. and Keller, U.
EJNMMI Research 11 (1): 77. 21 August 2021

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar, Ö., Brzezicha, B., Grunert, C., Kloetzel, P.M., Beier, C., Peuker, C.A., Keller, U., Pezzutto, A. and Busse, A.
Journal for ImmunoTherapy of Cancer 9 (7): e002410. 30 July 2021

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers, N., Duell, J., Fitzgerald, D., Kerkhoff, A., Noerenberg, D., Kaebisch, E., Acker, F., Fuhrmann, S., Leng, C., Welslau, M., Chemnitz, J., Middeke, J.M., Weber, T., Holtick, U., Trappe, R., Pfannes, R., Liersch, R., Spoer, C., Fuxius, S., Gebauer, N., Caillé, L., Geer, T., Koenecke, C., Keller, U., Claus, R., Mougiakakos, D., Mayer, S., Huettmann, A., Pott, C., Trummer, A., Wulf, G., Brunnberg, U., Bullinger, L., Hess, G., Mueller-Tidow, C., Glass, B., Lenz, G., Dreger, P. and Dietrich, S.
Blood Advances 5 (13): 2707-2716. 13 July 2021

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl, S., Goergen, H., Buehnen, I., Kobe, C., Moccia, A., Greil, R., Eichenauer, D.A., Zijlstra, J.M., Markova, J., Meissner, J., Feuring-Buske, M., Soekler, M., Beck, H.J., Willenbacher, W., Ludwig, W.D., Pabst, T., Topp, M.S., Hitz, F., Bentz, M., Keller, U.B., Kühnhardt, D., Ostermann, H., Hertenstein, B., Aulitzky, W., Maschmeyer, G., Vieler, T., Eich, H., Baues, C., Stein, H., Fuchs, M., Diehl, V., Dietlein, M., Engert, A. and Borchmann, P.
Lancet Haematology 8 (6): e398-e409. June 2021

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Schmitz, N., Truemper, L.H., Bouabdallah, K., Ziepert, M., Leclerc, M., Cartron, G., Jaccard, A., Reimer, P., Wagner-Drouet, E.M., Wilhelm, M., Sanhes, L., Lamy, T., de Leval, L., Rosenwald, A., Roussel, M., Kroschinsky, F.P., Lindemann, W.W., Dreger, P., Viardot, A., Milpied, N.J., Gisselbrecht, C., Wulf, G.G., Gyan, E., Gaulard, P., Bay, J.O., Glass, B., Poeschel, V., Damaj, G., Sibon, D., Delmer, A.J., Bilger, K., Banos, A., Haenel, M., Dreyling, M., Metzner, B., Keller, U., Braulke, F., Friedrichs, B., Nickelsen, M., Altmann, B. and Tournilhac, O.
Blood 137 (19): 2646-2656. 13 May 2021

Spontaneous non-sustained ventricular tachycardia and premature ventricular contractions and their prognostic relevance in patients with cancer in routine care.
Albrecht, A., Porthun, J., Eucker, J., Coats, A.J.S., von Haehling, S., Pezzutto, A., Karakas, M., Riess, H., Keller, U., Landmesser, U., Haverkamp, W., Anker, S.D. and Anker, M.S.
Cancers 13 (10): 2303. 12 May 2021

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Heider, M., Eichner, R., Stroh, J., Morath, V., Kuisl, A., Zecha, J., Lawatscheck, J., Baek, K., Garz, A.K., Rudelius, M., Deuschle, F.C., Keller, U., Lemeer, S., Verbeek, M., Götze, K.S., Skerra, A., Weber, W.A., Buchner, J., Schulman, B.A., Kuster, B., Fernández-Sáiz, V. and Bassermann, F.
Molecular Cell 81 (6): 1170-1186. 18 March 2021

ECG scoring for the evaluation of therapy-naïve cancer patients to predict cardiotoxicity.
Pohl, J., Mincu, R.I., Mrotzek, S.M., Wakili, R., Mahabadi, A.A., Potthoff, S.K., Siveke, J.T., Keller, U., Landmesser, U., Rassaf, T., Anker, M.S. and Totzeck, M.
Cancers 13 (6): 1197. 10 March 2021

Assessment of coronary artery disease during hospitalization for cancer treatment.
Mrotzek, S.M., Lena, A., Hadzibegovic, S., Ludwig, R., Al-Rashid, F., Mahabadi, A.A., Mincu, R.I., Michel, L., Johannsen, L., Hinrichs, L., Schuler, M., Keller, U., Anker, S.D., Landmesser, U., Rassaf, T., Anker, M.S. and Totzeck, M.
Clinical Research in Cardiology 110 (2): 200-210. February 2021

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann, P., Plütschow, A., Kobe, C., Greil, R., Meissner, J., Topp, M.S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Sökler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T.V., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Hüttmann, A., Wilhelm, M., Zijlstra, J.M., Moccia, A., Kuhnert, G., Bröckelmann, P.J., von Tresckow, B., Fuchs, M., Klimm, B., Rosenwald, A., Eich, H., Baues, C., Marnitz, S., Hallek, M., Diehl, V., Dietlein, M. and Engert, A.
Lancet Oncology 22 (2): 223-234. February 2021

Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial.
Voltin, C.A., Mettler, J., van Heek, L., Goergen, H., Müller, H., Baues, C., Keller, U., Meissner, J., Trautmann-Grill, K., Kerkhoff, A., Fuchs, M., Sasse, S., von Tresckow, B., Dietlein, M., Borchmann, P., Engert, A., Kobe, C. and Bröckelmann, P.J.
Clinical Cancer Research 27 (2): 402-407. January 2021

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke, S., Bröckelmann, P.J., Iaccarino, I., Garcia-Marquez, M., Borchmann, S., Jochims, F., Kotrova, M., Pal, K., Brüggemann, M., Hartmann, E., Sasse, S., Kobe, C., Mathas, S., Soekler, M., Keller, U., Bormann, M., Zimmermann, A., Richter, J., Fuchs, M., von Tresckow, B., Borchmann, P., Schlößer, H., von Bergwelt-Baildon, M., Rosenwald, A., Engert, A. and Klapper, W.
Blood 136 (25): 2851-2863. 17 December 2020

Authentication of primary murine cell lines by a microfluidics-based lab-on-chip system.
Hong, Y., Singh, N., Bamopoulos, S., Gjerga, E., Schmalbrock, L.K., Balabanian, K., Schick, M., Keller, U. and Wirth, M.
Biomedicines 8 (12): 590. 9 December 2020

CXCR4-targeted PET imaging of central nervous system B-cell lymphoma.
Herhaus, P., Lipkova, J., Lammer, F., Yakushev, I., Vag, T., Slotta-Huspenina, J., Habringer, S., Lapa, C., Pukrop, T., Hellwig, D., Wiestler, B., Buck, A.K., Deckert, M., Wester, H.J., Bassermann, F., Schwaiger, M., Weber, W.A., Menze, B. and Keller, U.
Journal of Nuclear Medicine 61 (12): 1765-1771. 1 December 2020

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A - results of a retrospective analysis.
Pouyiourou, M., Meyer, A., Stroux, A., Viardot, A., La Rosée, P., Maschmeyer, G., Kämpfe, D., Kahl, C., Vucinic, V., Monecke, A., Hirt, C., Weber, T., Meissner, J., Witzens-Harig, M., Böttcher, S., Schmalenberg, H., Marks, R., Prange-Krex, G., Kroschinsky, F., Hauf, E., Keller, U., Koch, K., Klapper, W., Herold, M. and Scholz, C.W.
Annals of Hematology 99 (12): 2821-2829. December 2020

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes, K., Hassan, Z.Z., Doffo, M.J., Schneeweis, C., Lier, S., Öllinger, R., Rad, R., Krämer, O.H., Keller, U., Saur, D., Reichert, M., Schneider, G. and Wirth, M.
Molecular Oncology 14 (12): 3048-3064. December 2020

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Klinghammer, K., Politz, O., Eder, T., Otto, R., Raguse, J.D., Albers, A., Kaufmann, A., Tinhofer, I., Hoffmann, J., Keller, U. and Keilholz, U.
Oncotarget 11 (41): 3688-3697. 13 October 2020

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L., Wirth, M., Dantes, Z., Steiger, K., Schunck, K., Langston, S., Lenhof, H.P., Coluccio, A., Orben, F., Slawska, J., Scherger, A., Saur, D., Müller, S., Rad, R., Weichert, W., Nilsson, J., Reichert, M., Schneider, G. and Keller, U.
Gut 69 (8): 1472-1482. August 2020

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial.
Bröckelmann, P.J., Goergen, H., Keller, U., Meissner, J., Ordemann, R., Halbsguth, T.V., Sasse, S., Sökler, M., Kerkhoff, A., Mathas, S., Hüttmann, A., Bormann, M., Zimmermann, A., Mettler, J., Fuchs, M., von Tresckow, B., Baues, C., Rosenwald, A., Klapper, W., Kobe, C., Borchmann, P. and Engert, A.
JAMA Oncology 6 (6): 872-880. June 2020

Final results of a phase I/II trial of the combination Bendamustine and Rituximab with Temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma.
Hess, G., Wagner, K., Keller, U., La Rosee, P., Atta, J., Hübel, K., Lerchenmueller, C., Schoendube, D., Witzens-Harig, M., Ruckes, C., Medler, C., van Oordt, C., Klapper, W., Theobald, M. and Dreyling, M.
HemaSphere 4 (3): e398. June 2020

Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention.
O'Connor, T., Zhou, X., Kosla, J., Adili, A., Garcia Beccaria, M., Kotsiliti, E., Pfister, D., Johlke, A.L., Sinha, A., Sankowski, R., Schick, M., Lewis, R., Dokalis, N., Seubert, B., Höchst, B., Inverso, D., Heide, D., Zhang, W., Weihrich, P., Manske, K., Wohlleber, D., Anton, M., Hoellein, A., Seleznik, G., Bremer, J., Bleul, S., Augustin, H.G., Scherer, F., Koedel, U., Weber, A., Protzer, U., Förster, R., Wirth, T., Aguzzi, A., Meissner, F., Prinz, M., Baumann, B., Höpken, U.E., Knolle, P.A., von Baumgarten, L., Keller, U. and Heikenwalder, M.
Cancer Cell 36 (3): 250-267. 16 September 2019

Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch, K., Meyer, A.H., Stroux, A., Hirt, C., Keller, U., Viardot, A., Marks, R., Schreiber, S., Pezzutto, A. and Scholz, C.W.
Annals of Hematology 94 (6): 981-988. June 2015

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.
Philipp-Abbrederis, K., Herrmann, K., Knop, S., Schottelius, M., Eiber, M., Lückerath, K., Pietschmann, E., Habringer, S., Gerngroß, C., Franke, K., Rudelius, M., Schirbel, A., Lapa, C., Schwamborn, K., Steidle, S., Hartmann, E., Rosenwald, A., Kropf, S., Beer, A.J., Peschel, C., Einsele, H., Buck, An.K., Schwaiger, M., Götze, K., Wester, H.J. and Keller, U.
EMBO Molecular Medicine 7 (4): 477-487. 1 April 2015

GP130 activation induces myeloma and collaborates with MYC.
Dechow, T., Steidle, S., Götze, K.S., Rudelius, M., Behnke, K., Pechloff, K., Kratzat, S., Bullinger, L., Fend, F., Soberon, V., Mitova, N., Li, Z., Thaler, M., Bauer, J., Pietschmann, E., Albers, C., Grundler, R., Schmidt-Supprian, M., Ruland, J., Peschel, C., Duyster, J., Rose-John, S., Bassermann, F. and Keller, U.
Journal of Clinical Investigation 124 (12): 5263-5274. 1 December 2014

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein, A., Fallahi, M., Schoeffmann, S., Steidle, S., Schaub, F.X., Rudelius, M., Laitinen, I., Nilsson, L., Goga, A., Peschel, C., Nilsson, J.A., Cleveland, J.L. and Keller, U.
Blood 124 (13): 2081-2090. 25 September 2014

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
Dörr, J.R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J.H.M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., Kratzat, S., Purfürst, B., Walenta, S., Mueller-Klieser, W., Gräler, M., Hummel, M., Keller, U., Buck, A.K., Dörken, B., Willmitzer, L., Reimann, M., Kempa, S., Lee, S. and Schmitt, C.A.
Nature 501 (7467): 421-425. 19 September 2013

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz, C.W., Pinto, A., Linkesch, W., Lindén, O., Viardot, A., Keller, U., Hess, G., Lastoria, S., Lerch, K., Frigeri, F., Arcamone, M., Stroux, A., Frericks, B., Pott, C. and Pezzutto, A.
Journal of Clinical Oncology 31 (3): 308-313. 20 January 2013

Review

Rationale for MYC imaging and targeting in pancreatic cancer.
Schneider, G., Wirth, M., Keller, U. and Saur, D.
EJNMMI Research 11 (1): 104. 12 October 2021

The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis, C., Hassan, Z., Schick, M., Keller, U. and Schneider, G.
British Journal of Cancer 124 (3): 531-538. 2 February 2021

Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy.
Wirth, M., Schick, M., Keller, U. and Krönke, J.
Cancers 12 (12): 3764. 14 December 2020

Letter

Simplified preanalytical laboratory procedures for therapeutic drug monitoring (TDM) in patients treated with high-dose methotrexate (HD-MTX) and glucarpidase.
Knörnschild, F.L., Liebig, S., Kießling, P., Prpic, M., Kim, T., Keller, U., Kappert, K., Schwartz, S. and Jahic, A.
Clinical Chemistry and Laboratory Medicine 15 July 2024 (In Press)

Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia.
Koslowski, S., Glauben, R., Habringer, S., Burmeister, T., Keller, U., Brüggemann, M., Gökbuget, N. and Schwartz, S.
Haematologica 109 (2): 661-665. February 2024

Genotype and intensive pretreatment influence outcome of acute myeloid leukemia patients treated with venetoclax in combination with hypomethylating agents or low-dose cytarabine: "real world" data from germany.
Braitsch, K., Schmalbrock, L.K., Jung, P., Bumeder, I., Kiewe, P., Hecker, J.S., Verbeek, M., Westermann, J., Bullinger, L., Keller, U., Bassermann, F., Krönke, J., Götze, K.S. and Rieger, K.
HemaSphere 6 (9): e759. September 2022

A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.
Wasilewski, D., Janz, M., Koch, A., Rosenwald, A., Keller, U., Vajkoczy, P., Faust, K., Anagnostopoulos, I. and Radke, J.
Acta Neurologica Belgica 123 (2): 667-670. April 2022

High-dose glucocorticoid treatment of near-fatal Bocavirus lung infection results in rapid recovery.
Obenaus, M., Schildgen, O., Schürmann, D., von Brünneck, A.C., Janz, M., Keller, U., Gebauer, B., Schilling, J., Schwartz, S., Weissbrich, B., Schneider, T., Hofmann, J. and Mathas, S.
ERJ Open Research 7 (2): 00060-2021. 12 April 2021

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.
Ferrero, S., Pastore, A., Scholz, C.W., Forstpointner, R., Pezzutto, A., Bergmann, L., Truemper, L., Finke, J., Keller, U., Ghione, P., Passera, R., Hiddemann, W., Weigert, O., Unterhalt, M. and Dreyling, M.
Leukemia 30 (4): 984-987. April 2016

Editorial

A hypoxia-epigenetics axis drives EMT in pancreatic cancer.
Wirth, M. and Schneider, G.
Cancer Research 84 (11): 1739-1741. 1 June 2024

A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?
Rieke, D.T. and Keller, U.
Haematologica 105 (11): 2504-2506. 1 November 2020